Ocular Therapeutix, Inc. · NASDAQ:OCUL

Ocular Therapeutix — ASCRS Annual Meeting 2022

11 slides from Ocular Therapeutix's conference presentation, April 2022

  1. Slide 1: Real-world Allergic Conjunctivitis Treatment Patterns of Eye Care Providers

    Real-world Allergic Conjunctivitis Treatment Patterns of Eye Care Providers William C. Christie, MD1; Preeya K. Gupta, MD2; Lena A. Dixit, MD3; Ella M. Gibson4; Srilatha Vantipalli, PhD4; Michael H. Goldstein, MD4 1Scott & Christie Eyecare Associates an EYESOUTH affiliate, Cranberry Township, PA; 2T

  2. Slide 2: Disclosures

    Disclosures • Presenter: William C. Christie was a participant in the current study. • Co-authors: Preeya K. Gupta and Lena A. Dixit were participants in this study. Ella M. Gibson, Srilatha Vantipalli, and Michael H. Goldstein are employees of Ocular Therapeutix. • Funding: This research was suppor

  3. Slide 3: Background

    Background Allergic Conjunctivitis There are no universally accepted strategies for the Therapeutic Options management of allergic conjunctivitis • Allergen identification and avoidance  Symptoms frequently resemble those of comorbid conditions such as dry eye or allergic rhinitis which • Cold comp

  4. Slide 4: Methods: Qualitative Online Survey

    Methods: Qualitative Online Survey Objective: To understand and characterize how eye care providers (ECPs) use existing AC therapies in clinical practice Sample Population Qualitative Online Survey  US-based ophthalmologists  Distributed between August and optometrists and September 2021  Differe

  5. Slide 5: Highly experienced ECPs from anterior segment specialties participated in the survey

    Highly experienced ECPs from anterior segment specialties participated in the survey Ophthalmologists OPHTHALMOLOGISTS’ SPECIALTIES (N=48) N=48 40% 33% Age, mean (SD) 50 (12) 30% 23% 21% 20% 18% Gender, M/F 62% / 36% Years in Practice, mean 10% 20 (12) 2% 2% 2% (SD) 0% Cataract Refractive Cornea Gla

  6. Slide 6: ECPs initially treat AC with dual activity agents, artificial tears and cool compresses

    ECPs initially treat AC with dual activity agents, artificial tears and cool compresses FIRST LINE THERAPY FOR ALLERGIC CONJUNCTIVITIS PREFERRED DUAL-ACTIVITY AGENT TO MANAGE (N=92) ALLERGIC CONJUNCTIVITIS (N=92) Ketotifen Preservative-Free Olopatadine 0.7% (Pazeo) Cool compresses 16.1% Ketotifen 0.

  7. Slide 7: Steroids are primarily used to manage moderate or severe AC symptoms

    Steroids are primarily used to manage moderate or severe AC symptoms DOES THE SEVERITY OF AC SYMPTOMS DETERMINE SEVERITY OF SYMPTOMS WHEN STEROIDS ARE WHEN YOU PRESCRIBE A STEROID? (N=92) INITIATED TO MANAGE AC (N=89) 80% 70% No 70% 3% 60% 50% 40% 30% 27% Yes 97% 20% 10% 3% 0% Almost all (97%) ECPs

  8. Slide 8: When treating with a steroid, half of ECPs also treat with dual-activity agents

    When treating with a steroid, half of ECPs also treat with dual-activity agents and preferred loteprednol over other steroids WHAT MEDICATION DO YOU USE PREFERRED STEROID FOR THE MANAGEMENT CONCOMITANTLY WITH STEROIDS? OF AC (N=92) 60% 50% Prednisolone 50% 17% Pred Forte 40% 12% Alrex 35% Pred Mild

  9. Slide 9: Misuse of steroid eye drops and the associated IOP side effects were substantial concerns

    Misuse of steroid eye drops and the associated IOP side effects were substantial concerns of ECPs MOST SUBSTANTIAL ISSUE ASSOCIATED WITH STEROID ESTIMATED PERCENT OF PATIENTS EYE (N=92) WHO MISUSE OR ABUSE STEROIDS 40% Ophthalmologists (N=48) Optometrists (N=44) 35% 60% 35% 30% 28% 50% 25% 40% 19% 2

  10. Slide 10: The greatest limitations of AC topical therapy were noncompliance and short duration of action

    The greatest limitations of AC topical therapy was noncompliance to eyedrop regimen and short duration of action WHAT DO YOU CONSIDER IS THE GREATEST LIMITATION OR DRAWBACK ASSOCIATED WITH CURRENT TREATMENT OPTIONS FOR AC? (N=92) Frequent dosing 9.0% Noncompliance of eyedrop regimen 18.8% Preservati

  11. Slide 11: AC Treatment Patterns Summary

    AC Treatment Patterns Summary Objective: : To understand and characterize how eye care providers (ECPs) use existing AC therapies in clinical practice Survey Findings • Most ophthalmologists and optometrists treat AC with topical dual-activity (mast cell stabilizer/antihistamine) agents, cool compre

Ocular Therapeutix — ASCRS Annual Meeting 2022 on 6ix